These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 31948072)

  • 21. Cetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids.
    Klöss S; Chambron N; Gardlowski T; Weil S; Koch J; Esser R; Pogge von Strandmann E; Morgan MA; Arseniev L; Seitz O; Köhl U
    Front Immunol; 2015; 6():543. PubMed ID: 26579120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced NK cell adoptive antitumor effects against breast cancer in vitro via blockade of the transforming growth factor-β signaling pathway.
    Zhao Y; Hu J; Li R; Song J; Kang Y; Liu S; Zhang D
    Onco Targets Ther; 2015; 8():1553-9. PubMed ID: 26124672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway.
    Viel S; Marçais A; Guimaraes FS; Loftus R; Rabilloud J; Grau M; Degouve S; Djebali S; Sanlaville A; Charrier E; Bienvenu J; Marie JC; Caux C; Marvel J; Town L; Huntington ND; Bartholin L; Finlay D; Smyth MJ; Walzer T
    Sci Signal; 2016 Feb; 9(415):ra19. PubMed ID: 26884601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medulloblastoma rendered susceptible to NK-cell attack by TGFβ neutralization.
    Powell AB; Yadavilli S; Saunders D; Van Pelt S; Chorvinsky E; Burga RA; Albihani S; Hanley PJ; Xu Z; Pei Y; Yvon ES; Hwang EI; Bollard CM; Nazarian J; Cruz CRY
    J Transl Med; 2019 Sep; 17(1):321. PubMed ID: 31547819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic blockade of activin-A improves NK cell function and antitumor immunity.
    Rautela J; Dagley LF; de Oliveira CC; Schuster IS; Hediyeh-Zadeh S; Delconte RB; Cursons J; Hennessy R; Hutchinson DS; Harrison C; Kita B; Vivier E; Webb AI; Degli-Esposti MA; Davis MJ; Huntington ND; Souza-Fonseca-Guimaraes F
    Sci Signal; 2019 Aug; 12(596):. PubMed ID: 31455725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platelets impair natural killer cell reactivity and function in endometriosis through multiple mechanisms.
    Du Y; Liu X; Guo SW
    Hum Reprod; 2017 Apr; 32(4):794-810. PubMed ID: 28184445
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blocking transforming growth factor-β signaling pathway augments antitumor effect of adoptive NK-92 cell therapy.
    Yang B; Liu H; Shi W; Wang Z; Sun S; Zhang G; Hu Y; Liu T; Jiao S
    Int Immunopharmacol; 2013 Oct; 17(2):198-204. PubMed ID: 23806302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients.
    Lee JC; Lee KM; Kim DW; Heo DS
    J Immunol; 2004 Jun; 172(12):7335-40. PubMed ID: 15187109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancer.
    Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
    J Immunol; 2005 Oct; 175(8):5541-50. PubMed ID: 16210663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Translating the anti-myeloma activity of Natural Killer cells into clinical application.
    Fionda C; Stabile H; Molfetta R; Soriani A; Bernardini G; Zingoni A; Gismondi A; Paolini R; Cippitelli M; Santoni A
    Cancer Treat Rev; 2018 Nov; 70():255-264. PubMed ID: 30326421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MICA immune complex formed with alpha 3 domain-specific antibody activates human NK cells in a Fc-dependent manner.
    Du C; Bevers J; Cook R; Lombana TN; Rajasekaran K; Matsumoto M; Spiess C; Kim JM; Ye Z
    J Immunother Cancer; 2019 Aug; 7(1):207. PubMed ID: 31387641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytokine-driven regulation of NK cell functions in tumor immunity: role of the MICA-NKG2D system.
    Zwirner NW; Fuertes MB; Girart MV; Domaica CI; Rossi LE
    Cytokine Growth Factor Rev; 2007; 18(1-2):159-70. PubMed ID: 17324607
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human natural killer cells and other innate lymphoid cells in cancer: Friends or foes?
    Vacca P; Munari E; Tumino N; Moretta F; Pietra G; Vitale M; Del Zotto G; Mariotti FR; Mingari MC; Moretta L
    Immunol Lett; 2018 Sep; 201():14-19. PubMed ID: 30439479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity.
    Lin CY; Chuang TF; Liao KW; Huang YJ; Pai CC; Chu RM
    Cancer Lett; 2008 Dec; 272(2):285-95. PubMed ID: 18760876
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cord blood natural killer cells expressing a dominant negative TGF-β receptor: Implications for adoptive immunotherapy for glioblastoma.
    Yvon ES; Burga R; Powell A; Cruz CR; Fernandes R; Barese C; Nguyen T; Abdel-Baki MS; Bollard CM
    Cytotherapy; 2017 Mar; 19(3):408-418. PubMed ID: 28109751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
    Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
    Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. To kill or not to kill - The role of the tumor microenvironment in shaping group 1 ILC functions.
    Müller NC; Romagnani C
    Semin Immunol; 2022 Nov; 61-64():101670. PubMed ID: 36372017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Editorial: TGF-β as a Key Regulator of NK and ILCs Development and Functions.
    Bottino C; Walzer T; Santoni A; Castriconi R
    Front Immunol; 2020; 11():631712. PubMed ID: 33542726
    [No Abstract]   [Full Text] [Related]  

  • 39. The TGF-β-induced up-regulation of NKG2DLs requires AKT/GSK-3β-mediated stabilization of SP1.
    Chen XH; Lu LL; Ke HP; Liu ZC; Wang HF; Wei W; Qi YF; Wang HS; Cai SH; Du J
    J Cell Mol Med; 2017 May; 21(5):860-870. PubMed ID: 28165192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML.
    Salomé B; Gomez-Cadena A; Loyon R; Suffiotti M; Salvestrini V; Wyss T; Vanoni G; Ruan DF; Rossi M; Tozzo A; Tentorio P; Bruni E; Riether C; Jacobsen EM; Jandus P; Conrad C; Hoenig M; Schulz A; Michaud K; Della Porta MG; Salvatore S; Ho PC; Gfeller D; Ochsenbein A; Mavilio D; Curti A; Marcenaro E; Steinle A; Horowitz A; Romero P; Trabanelli S; Jandus C
    Blood Adv; 2019 Nov; 3(22):3674-3687. PubMed ID: 31765481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.